

Paul Emery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5951088/publications.pdf>

Version: 2024-02-01

714
papers

88,232
citations

509

128
h-index

364

282
g-index

743
all docs

743
docs citations

743
times ranked

45615
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Pisotriquetral arthritis: "forgotten" joint in ultrasound imaging of the wrist" by Becciolini et al. Annals of the Rheumatic Diseases, 2022, 81, e98-e98.	0.5	2
2	Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 48-55.	0.5	31
3	Nailfold Microvascular Imaging by Dynamic Optical Coherence Tomography in Systemic Sclerosis: A Case-Controlled Pilot Study. Journal of Investigative Dermatology, 2022, 142, 1050-1057.	0.3	10
4	Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the "VEDERA" trial. Rheumatology, 2022, 61, 868-869.	0.9	0
5	Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum. Rheumatology, 2022, 61, 3192-3200.	0.9	7
6	Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study. Arthritis Research and Therapy, 2022, 24, 26.	1.6	6
7	COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1. Lancet Rheumatology, The, 2022, 4, e171-e172.	2.2	2
8	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 490-495.	0.5	10
9	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. Arthritis Research and Therapy, 2022, 24, 47.	1.6	7
10	Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open, 2022, 8, e002050.	1.8	18
11	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <sc>Pharmacogenomics-Driven</sc> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	1.5	15
12	P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren's Syndrome. Rheumatology, 2022, 61, .	0.9	1
13	OA13 Comprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. Rheumatology, 2022, 61, .	0.9	0
14	P215 In a treatment-naïve, early rheumatoid arthritis cohort, baseline ultrasound power Doppler synovitis and tenosynovitis are highly associated with remission when treated with first line etanercept + methotrexate (MTX) but not MTX alone. Rheumatology, 2022, 61, .	0.9	0
15	P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom. Rheumatology, 2022, 61, .	0.9	2
16	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. Scientific Data, 2022, 9, 196.	2.4	4
17	P214 Classifiable early RA shows heterogeneous imaging features and potential means of stratification. Rheumatology, 2022, 61, .	0.9	0
18	P217 Describing the evolution of concordance/discordance between DAS28-ESR and ultrasound power Doppler synovitis in a treatment-naïve early RA cohort. Rheumatology, 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , 2021, 60, 4048-4054.	0.9	23
20	Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 3380-3387.	0.9	16
21	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
22	Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 162-168.	0.5	54
23	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
24	Differential Binding of Sarilumab and Tocilizumab to IL-6R α and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 714-724.	1.0	28
25	How should we treat palindromic rheumatism? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 266-277.	1.6	11
26	Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. <i>Rheumatology</i> , 2021, 60, 1216-1225.	0.9	8
27	TNF- α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN- α Production and Enhancing T Cell Activation. <i>Journal of Immunology</i> , 2021, 206, 785-796.	0.4	33
28	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. <i>Rheumatology</i> , 2021, 60, 3607-3616.	0.9	5
29	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021, 13, 1868078.	2.6	17
30	COVID-19 vaccination and antirheumatic therapy. <i>Rheumatology</i> , 2021, 60, 3496-3502.	0.9	89
31	The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021, 8, 651748.	1.2	7
32	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	0.9	16
33	P207â€ƒA proposal for individually tailored rituximab treatment based on clinical and B-cell biomarkers for remission maintenance in ANCA associated vasculitis. <i>Rheumatology</i> , 2021, 60, .	0.9	0
34	Should we aim for personalized prevention in individuals at risk of rheumatoid arthritis?. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 621-622.	0.9	1
35	Clinical, Radiologic, and Functional Outcomes Following Methotrexate Withdrawal in Etanercept-Treated Patients with Active Early Rheumatoid Arthritis: A Subanalysis of COMET Year 2 by Week 52 DAS28 Status. <i>Open Rheumatology Journal</i> , 2021, 15, 31-38.	0.1	0
36	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18

#	ARTICLE	IF	CITATIONS
37	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1286-1298.	0.5	31
38	A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001768.	1.8	14
39	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review. <i>Arthritis Research and Therapy</i> , 2021, 23, 3.	1.6	18
40	OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, 3679-3688.	0.9	10
41	In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritis. <i>Rheumatology</i> , 2021, 60, 3156-3164.	0.9	7
42	Current issues in rheumatoid arthritis-associated interstitial lung disease. <i>Lancet Rheumatology</i> , The, 2021, 3, e798-e807.	2.2	17
43	Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-221160.	0.5	11
44	Treating rheumatoid arthritis to an imaging target produces better outcomes, or does it?. <i>Rheumatology</i> , 2021, 60, 3-4.	0.9	1
45	Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1109-1124.	1.9	4
46	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab086.	0.3	2
47	A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2021, 12, 803175.	2.2	8
48	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 146-150.	0.4	0
49	Receptor activator of nuclear factor kappa- β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 456-462.	0.4	1
50	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	0
51	SFRP4 Expression Is Linked to Immune-Driven Fibrotic Conditions, Correlates with Skin and Lung Fibrosis in SSc and a Potential EMT Biomarker. <i>Journal of Clinical Medicine</i> , 2021, 10, 5820.	1.0	10
52	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 146-150.	0.4	8
53	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	1
54	Receptor activator of nuclear factor kappa- β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 456-462.	0.4	8

#	ARTICLE	IF	CITATIONS
55	Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. <i>Rheumatology</i> , 2020, 59, 613-621.	0.9	14
56	Response to: "Ultrasound findings in palindromic rheumatism" by Sanmarti et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e31-e31.	0.5	2
57	Response to: "Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?" by Deng et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e84-e84.	0.5	2
58	Clinical trial and "real-world" data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e44-e44.	0.5	7
59	Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 493-501.	1.0	18
60	Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1549.	1.6	0
61	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. <i>Arthritis Care and Research</i> , 2020, 72, 959-964.	1.5	3
62	Muscle stiffness in rheumatoid arthritis is not altered or associated with muscle weakness: A shear wave elastography study. <i>Modern Rheumatology</i> , 2020, 30, 617-625.	0.9	9
63	Long-term follow-up of patients in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020, 59, 807-810.	0.9	8
64	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020, 47, 1338-1343.	1.0	10
65	Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 110, 102399.	3.0	25
66	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131.	0.5	206
67	Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2020, 7, 121-131.	1.1	17
68	B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 769-779.	2.9	16
69	O12 Effect of rituximab on RA-associated bronchiectasis and comparison of 5-year respiratory survival with TNFi. <i>Rheumatology</i> , 2020, 59, .	0.9	0
70	P12 Clinical responses, B cell depletion and treatment outcomes following rituximab biosimilar switch in RA: is there value in switching back?. <i>Rheumatology</i> , 2020, 59, .	0.9	1
71	P112 Muscles in myositis with normal MRI appearance have higher quantitative T2 compared to those in healthy controls. <i>Rheumatology</i> , 2020, 59, .	0.9	0
72	P115 Quantitative MRI of muscles is different in rheumatoid arthritis patients compared to healthy controls. <i>Rheumatology</i> , 2020, 59, .	0.9	0

#	ARTICLE	IF	CITATIONS
73	The Role of the Microbiome in Driving RA-Related Autoimmunity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 538130.	1.8	16
74	Pulmonary intravascular coagulopathy in COVID-19 pneumonia – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e460-e461.	2.2	14
75	Lessons for rituximab therapy in patients with rheumatoid arthritis. <i>Lancet Rheumatology</i> , The, 2020, 2, e497-e509.	2.2	20
76	It's never too soon to treat rheumatoid arthritis: finally, some supportive evidence. <i>Lancet Rheumatology</i> , The, 2020, 2, e311-e313.	2.2	2
77	The Role of Ultrasound Across the Inflammatory Arthritis Continuum: Focus on ‘At-Risk’ Individuals. <i>Frontiers in Medicine</i> , 2020, 7, 587827.	1.2	9
78	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. <i>Nature Communications</i> , 2020, 11, 6149.	5.8	71
79	Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 672-680.	0.9	15
80	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	1.6	2
81	Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. <i>Frontiers in Medicine</i> , 2020, 7, 498.	1.2	15
82	Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1414-1422.	0.5	32
83	Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 901-907.	0.5	33
84	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 115.	1.6	11
85	P200 – Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators. <i>Rheumatology</i> , 2020, 59, .	0.9	0
86	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e437-e445.	2.2	652
87	How Are Rheumatologists Managing Anticyclic Citrullinated Peptide Antibodies-positive Patients Who Do Not Have Arthritis?. <i>Journal of Rheumatology</i> , 2020, 47, 305-306.	1.0	17
88	Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1820-1828.	2.9	24
89	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	1.8	3
90	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 464-471.	0.5	14

#	ARTICLE	IF	CITATIONS
91	Reply. Arthritis and Rheumatology, 2020, 72, 1231-1233.	2.9	0
92	Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity. Frontiers in Immunology, 2020, 11, 1336.	2.2	8
93	T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: Implications for management. Scientific Reports, 2020, 10, 3669.	1.6	20
94	Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. Rheumatology, 2020, 59, 2838-2846.	0.9	5
95	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.5	1,860
96	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Annals of the Rheumatic Diseases, 2020, 79, 1023-1030.	0.5	8
97	Reduction in stiffness of proximal leg muscles during the first 6 months of glucocorticoid therapy for giant cell arteritis: A pilot study using shear wave elastography. International Journal of Rheumatic Diseases, 2019, 22, 1891-1899.	0.9	4
98	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials, 2019, 20, 429.	0.7	77
99	Normal values and test-retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle. British Journal of Radiology, 2019, 92, 20190143.	1.0	10
100	IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. Frontiers in Immunology, 2019, 10, 1535.	2.2	17
101	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 164.	1.6	24
102	Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial. Advances in Therapy, 2019, 36, 2384-2393.	1.3	3
103	Palindromic rheumatism as part of the rheumatoid arthritis continuum. Nature Reviews Rheumatology, 2019, 15, 687-695.	3.5	36
104	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. PLoS ONE, 2019, 14, e0223246.	1.1	11
105	Reductions in absolute neutrophil count with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety. Rheumatology, 2019, 58, .	0.9	0
106	Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience. Rheumatology, 2019, 58, .	0.9	0
107	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	2.2	76
108	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 887-895.	1.0	7

#	ARTICLE	IF	CITATIONS
109	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019, 71, 1812-1823.	2.9	89
110	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 831.	1.0	50
111	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 409-419.	1.1	18
112	Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti-“Cyclic Citrullinated Protein Antibody”-Positive At-Risk Adults Without Arthritis. <i>JAMA Network Open</i> , 2019, 2, e195394.	2.8	74
113	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019, 5, e000898.	1.8	14
114	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor”-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	0.9	26
115	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , 2019, 393, 2303-2311.	6.3	237
116	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome. <i>RMD Open</i> , 2019, 5, e000885.	1.8	14
117	244”-Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): results from a proof-of-concept phase II trial. <i>Rheumatology</i> , 2019, 58, .	0.9	0
118	Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 2015-2024.	0.9	13
119	089”-Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response. <i>Rheumatology</i> , 2019, 58, .	0.9	1
120	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. <i>RMD Open</i> , 2019, 5, e000840.	1.8	8
121	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1684-1686.	0.9	3
122	A Multicenter, Randomized, Placebo”-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	2.9	77
123	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1400-1409.	0.9	39
124	MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 781-786.	0.5	21
125	First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1138-1140.	0.5	15
126	Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 849-858.	0.9	75

#	ARTICLE	IF	CITATIONS
127	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
128	Muscle shear wave elastography in idiopathic inflammatory myopathies: a caseâ€“control study with MRI correlation. <i>Skeletal Radiology</i> , 2019, 48, 1209-1219.	1.2	53
129	The effect of ageing on shear wave elastography muscle stiffness in adults. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1755-1763.	1.4	96
130	FRI0637â€“...MUSCLES IN MYOSITIS PATIENTS WITH NORMAL MRI APPEARANCE HAVE HIGHER QUANTITATIVE T2 COMPARED TO THOSE IN HEALTHY CONTROLS. , 2019, , .		0
131	OP0021â€“...PREDICTING SEVERE INFECTION IN REPEAT CYCLES OF RITUXIMAB AND EFFECTS OF HYOGAMMAGLOBULINAEMIA FOR THE TREATMENT OF RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
132	THU0072â€“...ULTRASOUND PREDICTS IMMINENT PROGRESSION TO ARTHRITIS IN ANTI-CCP POSITIVE AT-RISK INDIVIDUALS. , 2019, , .		2
133	FRI0631â€“...MUSCLE STIFFNESS AND WEAKNESS IN RHEUMATOID ARTHRITIS â€“ A SHEAR WAVE ELASTOGRAPHY STUDY. , 2019, , .		0
134	THU0174â€“...CHARACTERIZATION OF REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB OR COMPARATORS. , 2019, , .		0
135	SAT0009â€“...THE EFFECT OF FCGR3A POLYMORPHISM ON THE INITIAL DEPTH OF B-CELL DEPLETION BY RITUXIMAB, FUNCTIONAL NK-CELL MEDIATED KILLING AND CLINICAL RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
136	THU0169â€“...JANUS KINASE INHIBITORS DEMONSTRATE EFFECTIVENESS IN A REAL-WORLD MULTI-BIOLOGIC DMARD REFRACTORY RHEUMATOID ARTHRITIS POPULATION. , 2019, , .		2
137	FRI0090â€“...SINGLE CENTRE COHORT OF REFRACTORY RHEUMATOID ARTHRITIS ALSO IDENTIFIES A RARE SUBGROUP OF MULTIPLE TARGETED THERAPY CLASS NON-RESPONSE. , 2019, , .		0
138	THU0605â€“...SHEAR WAVE ELASTOGRAPHY MUSCLE STIFFNESS MAY DIMINISH AFTER CORTICOSTEROID TREATMENT. , 2019, , .		0
139	THU0191â€“...UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-MONOTHERAPY STUDY. , 2019, , .		1
140	FRI0315â€“...SERUM INTERFERON SCORE PREDICTS CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND COMPOSITE RESPONSE INDEX IN SSC(CRISS). , 2019, , .		1
141	What Should Be the Primary Target of â€œTreat to Targetâ€“in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019, 46, 38-42.	1.0	24
142	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. <i>Rheumatology</i> , 2019, 58, 859-868.	0.9	108
143	Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 11-19.	1.0	2
144	Regression of Peripheral Subclinical Enthesopathy in Therapyâ€“Naive Patients Treated With Ustekinumab for Moderateâ€“toâ€“Severe Chronic Plaque Psoriasis: A Fiftyâ€“Twoâ€“Week, Prospective, Openâ€“Label Feasibility Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 626-631.	2.9	64

#	ARTICLE	IF	CITATIONS
145	Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 1353-1360.	0.9	14
146	Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 43-50.	0.5	25
147	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 304-312.	0.9	28
148	Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e28-e28.	0.5	3
149	Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. <i>European Journal of Rheumatology</i> , 2019, 6, 37-45.	1.3	9
150	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.	0.5	41
151	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Impact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) patients (PREDICTRA). <i>BMI Open</i> , 2018, 8, e019007.	0.8	7
152	Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1598-1606.	1.5	22
153	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
154	Transforming Growth Factor β 2 Activation Primes Canonical Wnt Signaling Through Downregulation of Axin2. <i>Arthritis and Rheumatology</i> , 2018, 70, 932-942.	2.9	25
155	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
156	Scleroderma fibroblasts suppress angiogenesis via TGF- β 2/caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 431-440.	0.5	26
157	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 412-416.	0.5	86
158	Validity of a 2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
159	Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2018, 57, 49-58.	0.9	55
160	Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era. <i>Arthritis Care and Research</i> , 2018, 70, 361-368.	1.5	12
161	Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 462-468.	1.5	12
162	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484

#	ARTICLE	IF	CITATIONS
163	Remission in psoriatic arthritis“where are we now?. Rheumatology, 2018, 57, 1321-1331.	0.9	16
164	The effect of unit, depth, and probe load on the reliability of muscle shear wave elastography: Variables affecting reliability of SWE. Journal of Clinical Ultrasound, 2018, 46, 108-115.	0.4	87
165	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Annals of the Rheumatic Diseases, 2018, 77, 165-174.	0.5	173
166	Defining and characterizing sustained remission in patients with rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 885-893.	1.0	6
167	The RA-MAP Consortium: a working model for academia“industry collaboration. Nature Reviews Rheumatology, 2018, 14, 53-60.	3.5	15
168	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 289-292.	0.5	22
169	Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Research, 2018, 7, 1512.	0.8	77
170	O11“Change in function, fatigue and pain in anti-CCP positive at-risk individuals predict progression to inflammatory arthritis. Rheumatology, 2018, 57, .	0.9	0
171	209“Normalisation of the American College of Rheumatology provisional composite response index in systemic sclerosis numerator for baseline data offers a measure of magnitude of response: results from a real-life observational study. Rheumatology, 2018, 57, .	0.9	0
172	e48“Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	3
173	222“Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. Rheumatology, 2018, 57, .	0.9	1
174	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International, 2018, 38, 2225-2231.	1.5	4
175	O18“The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) score: the first validated combined index predictive of future weight loss in systemic sclerosis. Rheumatology, 2018, 57, .	0.9	0
176	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology, 2018, 58, 254-259.	0.9	11
177	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 2018, 4, e000662.	1.8	18
178	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	0.9	42
179	Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Annals of the Rheumatic Diseases, 2018, 77, 1432-1439.	0.5	79
180	Characterization and Changes of Lymphocyte Subsets in Baricitinib“Treated Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1923-1932.	2.9	26

#	ARTICLE	IF	CITATIONS
181	Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 35.	1.2	1
182	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018, 35, 1535-1563.	1.3	56
183	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. <i>Pharmacoeconomics</i> , 2018, 36, 1015-1027.	1.7	15
184	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-280.	1.3	16
185	Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study. <i>Open Rheumatology Journal</i> , 2018, 12, 179-188.	0.1	1
186	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 115-120.	0.4	12
187	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 51-57.	0.5	201
188	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	1.5	16
189	Identifying arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e14-e14.	0.5	6
190	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1070-1077.	0.5	213
191	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
192	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 1440-1450.	2.9	194
193	Imminent rheumatoid arthritis can be identified in primary care. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e42-e42.	0.5	1
194	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
195	Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 486-490.	0.5	38
196	Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. <i>RMD Open</i> , 2017, 3, e000394.	1.8	28
197	02.17...Rheumatoid arthritis driven alteration in t-cell epigenetic programming. , 2017, , .		0
198	Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. <i>Journal of Rheumatology</i> , 2017, 44, 1688-1693.	1.0	23

#	ARTICLE	IF	CITATIONS
199	Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. <i>Rheumatology</i> , 2017, 56, 1348-1357.	0.9	153
200	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468.	6.3	360
201	Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. <i>Journal of Immunology</i> , 2017, 198, 4618-4628.	0.4	40
202	Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1743-1746.	0.5	32
203	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1688-1692.	0.5	17
204	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000410.	1.8	28
205	Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. <i>Rheumatology</i> , 2017, 56, kew431.	0.9	89
206	Modifying the trajectory of asthma—are there lessons from the use of biologics in rheumatology?. <i>Lancet, The</i> , 2017, 389, 1082-1084.	6.3	3
207	Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. <i>Rheumatology</i> , 2017, 56, 58-67.	0.9	5
208	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	1.5	18
209	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 88-95.	0.5	295
210	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
211	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 2093-2101.	0.9	59
212	Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. <i>Rheumatology International</i> , 2017, 37, 1789-1798.	1.5	20
213	An investigation into the reliability of shear wave elastography acquisition methods in muscle. <i>Clinical Radiology</i> , 2017, 72, S11-S12.	0.5	0
214	Does unit of reporting, depth and probe load influence the reliability of muscle shear wave elastography?. <i>Clinical Radiology</i> , 2017, 72, S12.	0.5	0
215	Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 19-30.	1.4	87
216	Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1986-1991.	0.5	90

#	ARTICLE	IF	CITATIONS
217	The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1706-1712.	1.0	102
218	What can palindromic rheumatism tell us?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 90-98.	1.4	22
219	Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. <i>RMD Open</i> , 2017, 3, e000550.	1.8	20
220	03.24â€¦Effect of tocilizumab therapy on il-6 signalling pathway in early rheumatoid arthritis patients. , 2017, , .		0
221	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
222	Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. <i>Journal of Rheumatology</i> , 2017, 44, 1331-1340.	1.0	6
223	Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1829-1836.	0.5	90
224	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
225	Individuals at risk of rheumatoid arthritis â€œ The evolving story. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 1-2.	1.4	2
226	02.18â€¦Can rankl serum levels predict future progression to rheumatoid arthritis in early arthritis clinic patients?. , 2017, , .		0
227	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 303.	0.8	9
228	The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound. <i>European Journal of Rheumatology</i> , 2017, 4, 118-121.	1.3	8
229	An investigation into the variability between different shear wave elastography systems in muscle. <i>Medical Ultrasonography</i> , 2017, 19, 392.	0.4	55
230	05.03â€¦Differential methylation profile of tnf-signalling genes in t-cells and monocytes. , 2017, , .		0
231	Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 607-613.	0.4	7
232	Six-joint ultrasound in rheumatoid arthritis: a feasible approach for implementing ultrasound in remission. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 853-856.	0.4	3
233	The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. <i>Discovery Medicine</i> , 2017, 24, 191-200.	0.5	13
234	The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. <i>Rheumatology</i> , 2016, 55, kev343.	0.9	25

#	ARTICLE	IF	CITATIONS
235	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 170-177.	0.5	48
236	Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy. <i>Oxford Medical Case Reports</i> , 2016, 2016, omw027.	0.2	9
237	Recent Trends of Ultrasound in Rheumatology. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 11.	0.4	0
238	112â€¦A Qualitative Exploration of the Symptoms Experienced by People with Palindromic Rheumatism. <i>Rheumatology</i> , 2016, , .	0.9	0
239	A new window of opportunity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 260-266.	2.0	17
240	Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo: TableA1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e65-e65.	0.5	9
241	Response to: â€˜Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another considerationâ€™™ by Marshall<i> et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e38-e38.	0.5	7
242	Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1902-1908.	0.5	93
243	Musculoskeletal ultrasound in rheumatology in <scp>K</scp>orea: targeted ultrasound initiative survey. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 335-342.	0.9	4
244	Response to: â€˜Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differencesâ€™™ by Shah. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e61-e61.	0.5	1
245	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 294.	1.6	27
246	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1501-1505.	0.5	17
247	Fatigue in primary SjÃ¶rgren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	1.8	77
248	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 61.	0.8	8
249	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	2.6	21
250	A Phase IIb Study of ABTâ€¦494, a Selective JAKâ€¦1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Antiâ€¦Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2867-2877.	2.9	149
251	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1428-1437.	0.5	232
252	Efficacy and Safety of Subcutaneous Golimumab in Methotrexateâ€¦Naive Patients With Rheumatoid Arthritis: Fiveâ€¦Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016, 68, 744-752.	1.5	32

#	ARTICLE	IF	CITATIONS
253	Review: Preclinical Rheumatoid Arthritis: Progress Toward Prevention. <i>Arthritis and Rheumatology</i> , 2016, 68, 779-788.	2.9	81
254	A phase I pharmacokinetics trial comparing PFâ€05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 129-138.	1.1	48
255	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaudâ€™s Phenomenon. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 342.	0.8	18
256	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritisâ€™ results from the IDEA study. <i>Rheumatology</i> , 2016, 55, 2181-2190.	0.9	21
257	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016, 55, 1458-1465.	0.9	15
258	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. <i>Rheumatology</i> , 2016, 55, 2273-2275.	0.9	2
259	Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e40-e40.	0.5	9
260	Response to: â€™Reporting of potential immunogenicity with biologic drugs: clarity and accuracy requiredâ€™ by Moots <i>et al</i> : Table A1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e25-e25.	0.5	5
261	The prevalence of tenosynovitis of the interosseous tendons of the hand in patients with rheumatoid arthritis. <i>European Radiology</i> , 2016, 26, 444-450.	2.3	19
262	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
263	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
264	Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2060-2067.	0.5	99
265	Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms â€™ a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1452-1456.	0.5	59
266	Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1114-1119.	0.5	25
267	Introduction. <i>Current Opinion in Rheumatology</i> , 2016, 28, 259.	2.0	0
268	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , 2016, 55, 1177-1187.	0.9	31
269	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Preâ€™Specified Analysis of Two Phase III Trials. <i>Arthritis Care and Research</i> , 2016, 68, 299-307.	1.5	6
270	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.5	98

#	ARTICLE	IF	CITATIONS
271	Glucocorticoids and Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 33-46.	0.8	47
272	Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 408-412.	0.5	63
273	Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2188-2192.	0.5	68
274	Anti- <i>Porphyromonas gingivalis</i> Antibodies in Rheumatoid Arthritis: Comment on the Article by Seror et al. <i>Arthritis and Rheumatology</i> , 2015, 67, 3329-3330.	2.9	2
275	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325.	1.6	16
276	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ranging Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2591-2600.	2.9	86
277	012. Halo Naevi, Vitiligo and Diffuse Alopecia Areata Associated with Tocilizumab Therapy. <i>Rheumatology</i> , 2015, , .	0.9	0
278	060. Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept following the withdrawal of all Treatment in Patients with Early Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
279	295. Flow-Based Cell-Specific Interferon Signature as a Biomarker in Systemic Lupus Erythematosus. <i>Rheumatology</i> , 2015, , .	0.9	0
280	The OMERACT MRI in Arthritis Working Group Update on Status and Future Research Priorities. <i>Journal of Rheumatology</i> , 2015, 42, 2470-2472.	1.0	18
281	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015, 373, 2534-2548.	13.9	803
282	Etanercept Tapering in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2015, 372, 489-490.	13.9	1
283	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24...months, with a 12-month, double-blind treatment period. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 19-26.	0.5	201
284	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2165-2174.	0.5	33
285	Brief Report: Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 1586-1591.	2.9	82
286	A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. <i>Rheumatology International</i> , 2015, 35, 1837-1849.	1.5	20
287	Remission in rheumatoid arthritis: is it all the same?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 575-586.	1.3	11
288	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36

#	ARTICLE	IF	CITATIONS
289	Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1734-1738.	0.5	33
290	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 2489-2498.	6.3	389
291	High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 185-189.	0.5	95
292	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2015, 55, kev373.	0.9	9
293	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1195-1201.	0.5	48
294	Exciting times for RA research. <i>Nature Reviews Rheumatology</i> , 2015, 11, 69-70.	3.5	4
295	The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 897-903.	0.5	83
296	B-cell depletion. , 2015, , 472-478.		2
297	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0143970.	1.1	45
298	Is localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for prevention. <i>Discovery Medicine</i> , 2015, 20, 129-35.	0.5	23
299	Early Arthritis. <i>Rheumatology</i> , 2014, 53, i16-i16.	0.9	0
300	Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1077-1087.	1.0	29
301	Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 511.	1.6	21
302	Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions. <i>Journal of Rheumatology</i> , 2014, 41, 383-385.	1.0	3
303	Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-19.	1.4	64
304	The Microanatomic Basis of Finger Clubbing – A High-resolution Magnetic Resonance Imaging Study. <i>Journal of Rheumatology</i> , 2014, 41, 523-527.	1.0	14
305	Role of golimumab for the treatment of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 245-258.	0.3	1
306	Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. <i>Rheumatology</i> , 2014, 53, 186-194.	0.9	56

#	ARTICLE	IF	CITATIONS
307	The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1975-1982.	0.5	90
308	Is the Glass Half Full or Half Empty? Comment on the Article by GÄrtner et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 1055-1056.	2.9	1
309	Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1â€“2â€“years. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1923-1928.	0.5	78
310	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€“Scale and Power Doppler Ultrasound. <i>Arthritis Care and Research</i> , 2014, 66, 432-439.	1.5	79
311	A1.9â€“Pilot work towards discovery of novel diagnostic biomarker for rheumatoid arthritis using combinations of chemokine receptor expression on peripheral blood cell-subsets. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A4.1-A4.	0.5	0
312	Choosing the Right Rituximab Dose for the Right Patient: Comment on the Article by Bredemeier et al. <i>Arthritis Care and Research</i> , 2014, 66, 1591-1593.	1.5	1
313	<i>MTHFR</i> functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. <i>Pharmacogenomics</i> , 2014, 15, 467-475.	0.6	16
314	The 'Switchâ€“ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 452.	0.8	20
315	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
316	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
317	Nonsteroidal Antiâ€“inflammatory Drugs, Gastroprotection, and Benefitâ€“Risk. <i>Pain Practice</i> , 2014, 14, 378-395.	0.9	51
318	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.5	166
319	Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. <i>Rheumatology</i> , 2014, 53, 1560-1569.	0.9	178
320	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.5	270
321	Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imagingâ€“Detected Synovitis and Radiographic Progression. <i>Arthritis and Rheumatology</i> , 2014, 66, 794-802.	2.9	52
322	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 349-356.	0.5	308
323	Certolizumab pegol in rheumatoid arthritis: current update. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 841-850.	1.4	10
324	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	13.9	169

#	ARTICLE	IF	CITATIONS
325	Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1968-1974.	0.5	75
326	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 420-427.	0.5	37
327	Why is there persistent disease despite biologic therapy? Importance of early intervention. <i>Arthritis Research and Therapy</i> , 2014, 16, 115.	1.6	14
328	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. <i>Journal of Rheumatology</i> , 2014, 41, 398-406.	1.0	71
329	Reply. <i>Arthritis and Rheumatology</i> , 2014, 66, 3245-3246.	2.9	0
330	An immunological biomarker to predict MTX response in early RA. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2047-2053.	0.5	51
331	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.5	87
332	Response to Dr Bredemeier's letter. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e34-e34.	0.5	0
333	Response to: "Which B-cell subset should we target in lupus?" by Ferraccioli and Houssiau. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e20-e20.	0.5	3
334	Biologics in systemic lupus erythematosus: current options and future perspectives. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 440-447.	0.2	7
335	Biologics in rheumatoid arthritis: where are we going?. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBT / Over	0.2	6
336	Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 909-912.	0.5	39
337	Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 1239-1246.	1.0	9
338	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
339	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.5	659
340	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
341	Emergence of proinflammatory autoreactive T-cell responses in preclinical rheumatoid arthritis. <i>Lancet, The</i> , 2014, 383, S22.	6.3	3
342	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , 2014, 50, 59-66.	3.0	59

#	ARTICLE	IF	CITATIONS
343	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	6.3	232
344	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2014, 383, S36.	6.3	15
345	Defining populations at risk of rheumatoid arthritis: the first steps to prevention. <i>Nature Reviews Rheumatology</i> , 2014, 10, 521-530.	3.5	22
346	Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. <i>Clinical Biomechanics</i> , 2014, 29, 811-814.	0.5	5
347	A1.52â€¦TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A22.1-A22.	0.5	0
348	1.63â€¦IL-7 drives the tissue architecture of the RA synovium providing a niche for B-cells to mature. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A27.2-A28.	0.5	0
349	Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program. <i>PLoS ONE</i> , 2014, 9, e87379.	1.1	71
350	Skin imaging in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2014, 1, 111-116.	1.3	18
351	Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 653-60.	0.4	18
352	Brief Report: Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease Relates to HLAâ€¦B27. <i>Arthritis and Rheumatism</i> , 2013, 65, 2274-2278.	6.7	59
353	The TICOPA protocol (Tight COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 101.	0.8	89
354	B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 761-772.	1.3	10
355	Etanercept in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1441-1450.	1.4	7
356	Targeting Interleukin-6 in Rheumatoid Arthritis. <i>Drugs</i> , 2013, 73, 341-356.	4.9	69
357	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 382, 1705-1713.	6.3	518
358	Assessment of umbilical cord tissue as a source of mesenchymal stem cell/endothelial cell mixtures for bone regeneration. <i>Regenerative Medicine</i> , 2013, 8, 569-581.	0.8	21
359	Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 71-86.	1.0	10
360	Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1845-1851.	0.5	77

#	ARTICLE	IF	CITATIONS
361	Evaluation of Serum Biomarkers Associated with Radiographic Progression in Methotrexate-naive Rheumatoid Arthritis Patients Treated with Methotrexate or Golimumab. <i>Journal of Rheumatology</i> , 2013, 40, 590-598.	1.0	7
362	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1897-1904.	0.5	114
363	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013, 65, 88-97.	6.7	22
364	Is there a place for initial treatment with biological DMARDs in the early phase of RA?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 537-554.	1.4	8
365	Creative trial design in RA: optimizing patient outcomes. <i>Nature Reviews Rheumatology</i> , 2013, 9, 183-194.	3.5	16
366	Rituximab biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1049-1062.	1.4	34
367	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet, The</i> , 2013, 381, 1541-1550.	6.3	568
368	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.5	80
369	Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?. <i>Clinical Rheumatology</i> , 2013, 32, 151-159.	1.0	28
370	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.5	183
371	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
372	Autoantibodies to Posttranslationally Modified Type II Collagen as Potential Biomarkers for Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1702-1712.	6.7	59
373	Allele dose association of the C5orf30rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, n/a-n/a.	6.7	20
374	Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1032-1036.	0.5	24
375	The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 992-995.	0.5	73
376	Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1496-1502.	0.5	304
377	Metaanalysis of the Association of Smoking and <i>PTPN22</i> R620W Genotype on Autoantibody Status and Radiological Erosions in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1048-1053.	1.0	15
378	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.5	114

#	ARTICLE	IF	CITATIONS
379	Golimumab, a Human Anti-“Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1- and 2-Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double-“Blind, Placebo-“Controlled Study. <i>Arthritis Care and Research</i> , 2013, 65, 1732-1742.	1.5	33
380	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 329-336.	0.5	158
381	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
382	Republished: A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. <i>Postgraduate Medical Journal</i> , 2013, 89, 231-240.	0.9	19
383	Dr. Keystone, et al, reply. <i>Journal of Rheumatology</i> , 2013, 40, 732.2-733.	1.0	0
384	Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 463-464.	0.5	14
385	Value of Ultrasound in Rheumatologic Diseases. <i>Journal of Korean Medical Science</i> , 2013, 28, 497.	1.1	15
386	LDL Cholesterolemia as a Novel Risk Factor for Radiographic Progression of Rheumatoid Arthritis: A Single-Center Prospective Study. <i>PLoS ONE</i> , 2013, 8, e68975.	1.1	14
387	Comparison of ultrasonography and magnetic resonance imaging for the assessment of clinically defined knee enthesitis in spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 933-6.	0.4	10
388	Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. <i>Rheumatology</i> , 2012, 51, v22-v30.	0.9	85
389	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1316-1321.	0.5	160
390	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2035-2043.	0.5	69
391	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 799-803.	0.5	97
392	Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?. <i>Rheumatology</i> , 2012, 51, 270-274.	0.9	13
393	Ultrasonographic Assessment of Nail in Psoriatic Disease Shows a Link between Onychopathy and Distal Interphalangeal Joint Extensor Tendon Enthesopathy. <i>Dermatology</i> , 2012, 225, 231-235.	0.9	134
394	Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 1131-1132.	0.9	6
395	Ten-year follow-up of SpA-related oligoarthritis involving the knee: the presence of psoriasis but not HLA-B27 or baseline MRI bone oedema predicts outcome. <i>Rheumatology</i> , 2012, 51, 1099-1106.	0.9	7
396	Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, e2-e2.	0.5	23

#	ARTICLE	IF	CITATIONS
397	Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study. <i>Journal of Rheumatology</i> , 2012, 39, 2238-2246.	1.0	65
398	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 638-641.	0.5	354
399	Combination etanercept and methotrexate provides better disease control in very early (≤ 4 months) versus early rheumatoid arthritis (> 4 months and ≤ 2 years): post hoc analyses from the COMET study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 989-992.	0.5	74
400	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1640-1645.	0.5	20
401	Biological therapy for rheumatoid arthritis: where are we now?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, 12-18.	0.2	9
402	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1973-1979.	0.5	57
403	Towards an optimum strategy in rheumatoid arthritis. <i>Lancet, The</i> , 2012, 379, 1682-1684.	6.3	6
404	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	0.9	115
405	The evolution of ultrasound in rheumatology. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 399-411.	1.2	24
406	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 553-556.	0.5	136
407	Infliximab Treatment Increases Left Ventricular Ejection Fraction in Patients with Rheumatoid Arthritis: Assessment of Heart Function by Echocardiography, Endothelin 1, Interleukin 6, and NT-pro Brain Natriuretic Peptide. <i>Journal of Rheumatology</i> , 2012, 39, 701-706.	1.0	50
408	The role of tocilizumab in the management of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1277-1289.	1.4	26
409	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 319-326.	0.5	234
410	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Postgraduate Medical Journal</i> , 2012, 88, 482-486.	0.9	19
411	Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3150-3155.	6.7	84
412	Changing Crohn's disease management: Need for new goals and indices to prevent disability and improve quality of life. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S224-S234.	0.6	73
413	IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522). <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 131-139.	1.6	75
414	Certolizumab pegol for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 235-249.	1.4	37

#	ARTICLE	IF	CITATIONS
415	Transcriptional profile of native CD271+ multipotential stromal cells: Evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2632-2643.	6.7	116
416	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012, 11, 357-364.	2.5	209
417	Therapy Switching, Augmentation, and Discontinuation in Patients with Osteoarthritis and Chronic Low Back Pain. <i>Pain Practice</i> , 2012, 12, 457-468.	0.9	34
418	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , 2012, 33, 741-749.	1.1	36
419	Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 66-70.	1.5	19
420	Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2012, 64, 418-422.	6.7	130
421	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. <i>Blood</i> , 2012, 120, 964-964.	0.6	5
422	Fcγ3RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. <i>PLoS ONE</i> , 2012, 7, e28918.	1.1	49
423	Infliximab: 12 years of experience. <i>Arthritis Research and Therapy</i> , 2011, 13, S2.	1.6	60
424	Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1746-1751.	0.5	29
425	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1895-1904.	0.5	345
426	Optical Coherence Tomography: A New Tool to Assess Nail Disease in Psoriasis?. <i>Dermatology</i> , 2011, 222, 311-313.	0.9	41
427	Improvements in Participation in Usual Daily Activities in Patients with Rheumatoid Arthritis Treated with Abatacept. <i>Value in Health</i> , 2011, 14, 361-370.	0.1	7
428	MRI for the assessment and monitoring of RA—what can it tell us?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 185-189.	3.5	7
429	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
430	New therapies in the management of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 245-251.	2.0	61
431	NSAIDs inhibit in vitro MSC chondrogenesis but not osteogenesis: implications for mechanism of bone formation inhibition in man. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 525-534.	1.6	60
432	A randomised, controlled study of outcome and cost effectiveness for RA patients attending nurse-led rheumatology clinics: Study protocol of an ongoing nationwide multi-centre study. <i>International Journal of Nursing Studies</i> , 2011, 48, 995-1001.	2.5	8

#	ARTICLE	IF	CITATIONS
433	Golimumab – a new tool in the armoury against inflammatory arthritis. <i>Annals of Medicine</i> , 2011, 43, 133-141.	1.5	14
434	Foot health needs in people with systemic sclerosis: an audit of foot health care provision. <i>Clinical Rheumatology</i> , 2011, 30, 1611-1615.	1.0	15
435	Biomarkers in the Management of Scleroderma: An Update. <i>Current Rheumatology Reports</i> , 2011, 13, 4-12.	2.1	22
436	Quantitative magnetization transfer ultrashort echo time imaging of the Achilles tendon. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1372-1376.	1.9	38
437	Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review. <i>Arthritis Care and Research</i> , 2011, 63, 660-665.	1.5	14
438	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
439	Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion. <i>Arthritis and Rheumatism</i> , 2011, 63, 603-608.	6.7	72
440	The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. <i>Arthritis and Rheumatism</i> , 2011, 63, 1200-1210.	6.7	104
441	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3038-3047.	6.7	191
442	Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2011, 63, 3712-3722.	6.7	79
443	International disparities in access to anti-TNF therapy. <i>Nature Reviews Rheumatology</i> , 2011, 7, 197-198.	3.5	3
444	Remission in inflammatory arthritis: a new immunological target. <i>Immunotherapy</i> , 2011, 3, 459-463.	1.0	3
445	Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. <i>Journal of Rheumatology</i> , 2011, 38, 2039-2044.	1.0	101
446	Relationship between patient-reported disease severity and other clinical outcomes in osteoarthritis: a European perspective. <i>Journal of Medical Economics</i> , 2011, 14, 381-389.	1.0	13
447	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	0.9	12
448	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
449	Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. <i>Rheumatology</i> , 2011, 50, 2223-2232.	0.9	51
450	Myofibroblast specific gene expression signature in systemic sclerosis, more than TGF- β induced activation. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A31-A31.	0.5	0

#	ARTICLE	IF	CITATIONS
451	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 98-103.	0.5	55
452	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 423-427.	0.5	101
453	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2126-2130.	0.5	32
454	Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group. <i>Journal of Rheumatology</i> , 2011, 38, 2031-2033.	1.0	14
455	Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1968-1974.	0.5	56
456	Reduced IL-7 serum titres are associated with progression towards rheumatoid arthritis in less than 6 months inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A2-A2.	0.5	0
457	Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 792-798.	0.5	185
458	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71
459	Certolizumab pegol in rheumatoid arthritis: a review of Phase III clinical trials and its role in real-life clinical practice. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 517-527.	0.3	3
460	Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 184-187.	0.5	20
461	An ultrasonographic study of metatarsophalangeal joint pain: synovitis, structural pathology and their relationship to symptoms and function. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2140-2143.	0.5	17
462	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 886-890.	0.5	64
463	Cell receptor-ligand interaction, signalling, activation and apoptosis: 21. Pregnenolone Sulphate is Similar to Dexamethasone in Suppressing the Unfettered Secretion of Hyaluronan: In Vitro Study on Cultured Synovial Fibroblasts from Patients with Longstanding Rheumatoid Arthritis. <i>Rheumatology</i> , 2011, 50, iii50-iii52.	0.9	0
464	Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1826-1830.	0.5	134
465	The Changing Management of Inflammatory Arthritis. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 403-407.	0.5	0
466	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1572-1573.	0.5	32
467	CONDOR: time to review our treatment with NSAIDs?. <i>The Prescriber</i> , 2010, 21, 7-8.	0.1	0
468	Care needs to be taken when reviewing malignancy data reported from observational studies. Comment on review by Onel and Onel. <i>Arthritis Care and Research</i> , 2010, 63, n/a-n/a.	1.5	0

#	ARTICLE	IF	CITATIONS
469	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. <i>Arthritis and Rheumatism</i> , 2010, 62, 674-682.	6.7	104
470	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
471	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
472	Delay in receiving rheumatology care leads to long-term harm. <i>Arthritis and Rheumatism</i> , 2010, 62, 3519-3521.	6.7	54
473	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
474	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
475	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 101.	1.0	6
476	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502.	0.5	136
477	Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1926-1928.	0.5	101
478	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1054-1057.	0.5	55
479	The American College of Rheumatology/European League Against Rheumatism Criteria for the classification of rheumatoid arthritis: a game changer. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1575-1576.	0.5	9
480	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 666-670.	0.5	73
481	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203
482	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1407-1408.	0.5	9
483	Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 37-43.	1.2	22
484	Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 1971-1974.	0.9	46
485	Aspects of TNF inhibitor therapy in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 325-330.	0.9	19
486	Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study. <i>Rheumatology</i> , 2010, 49, 1093-1100.	0.9	49

#	ARTICLE	IF	CITATIONS
487	Differential pattern of expression of caveolin-1 and AIF-1 in chronic graft-versus-host disease suggests a specific role in the pathogenesis of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A24-A25.	0.5	0
488	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. <i>Rheumatology</i> , 2010, 49, 1894-1899.	0.9	25
489	Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 510-516.	0.5	249
490	Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. <i>Journal of Rheumatology</i> , 2010, 37, 558-567.	1.0	265
491	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578.	0.5	47
492	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1158-1161.	0.5	115
493	New biologic for treating rheumatoid arthritis: clinical trial experience with tocilizumab. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 17-24.	0.3	0
494	The evidence for whole-spine MRI in the assessment of axial spondyloarthritis. <i>Rheumatology</i> , 2010, 49, 426-432.	0.9	20
495	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 813-816.	0.5	62
496	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	1.0	83
497	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
498	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
499	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1785-1796.	0.3	554
500	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1629-1635.	0.5	296
501	Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1636-1642.	0.5	169
502	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
503	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
504	Aspects of TNF inhibitor therapy in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 325-330.	0.9	11

#	ARTICLE	IF	CITATIONS
505	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , 2009, 18, 2518-2522.	1.4	78
506	Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1429-1441.	1.0	89
507	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. <i>Journal of Rheumatology</i> , 2009, 36, 1816-1824.	1.0	168
508	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2009, 18, 2693-2699.	1.4	93
509	Reducing Invasiveness, Duration, and Cost of Magnetic Resonance Imaging in Rheumatoid Arthritis by Omitting Intravenous Contrast Injection â€” Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?. <i>Journal of Rheumatology</i> , 2009, 36, 1806-1810.	1.0	91
510	The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. <i>Rheumatology</i> , 2009, 48, 1283-1289.	0.9	58
511	Clinical and imaging efficacy of infliximab in HLAâ€”B27â€”Positive patients with magnetic resonance imagingâ€”determined early sacroiliitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 946-954.	6.7	262
512	Reâ€”treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: Comment on the article by Thurlings et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 1867-1867.	6.7	3
513	Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with diseaseâ€”modifying antirheumatic drugs: A clinical and imaging comparative study. <i>Arthritis and Rheumatism</i> , 2009, 60, 1915-1922.	6.7	130
514	Golimumab, a human antiâ€”tumor necrosis factor Î± monoclonal antibody, injected subcutaneously every four weeks in methotrexateâ€”naive patients with active rheumatoid arthritis: Twentyâ€”fourâ€”week results of a phase III, multicenter, randomized, doubleâ€”blind, placeboâ€”controlled study of golimumab before methotrexate as firstâ€”line therapy for earlyâ€”onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387
515	Reevaluation of the interaction between HLAâ€”DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibodyâ€”positive and autoantibodyâ€”negative rheumatoid arthritis in a large UK Caucasian population. <i>Arthritis and Rheumatism</i> , 2009, 60, 2565-2576.	6.7	86
516	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1592-1600.	6.7	78
517	The role of biomarkers in the management of patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 371-377.	2.1	12
518	Rheumatoid arthritis: what has changed?. <i>Skeletal Radiology</i> , 2009, 38, 109-112.	1.2	12
519	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009, 41, 1313-1318.	9.4	306
520	Robotic multiwell planar patch-clamp for native and primary mammalian cells. <i>Nature Protocols</i> , 2009, 4, 244-255.	5.5	95
521	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study. <i>Journal of Rheumatology</i> , 2009, 36, 736-742.	1.0	114
522	Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 1256-1264.	1.0	47

#	ARTICLE	IF	CITATIONS
523	The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities. <i>Journal of Rheumatology</i> , 2009, 36, 1803-1805.	1.0	8
524	MRI predicts response to anti-TNF in ankylosing spondylitis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 123-126.	0.3	0
525	Comparison of autoinflammation and autoimmunity using TRAPS and rheumatoid arthritis as prototypes of these conditions. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 681-695.	0.3	2
526	Costimulation blockade in rheumatic diseases: where we are?. <i>Current Opinion in Rheumatology</i> , 2009, 21, 244-250.	2.0	25
527	B cell targets in rheumatoid arthritis. , 2009, , 1-26.		0
528	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008, 58, 953-963.	6.7	159
529	The shared epitope hypothesis in rheumatoid arthritis: Evaluation of alternative classification criteria in a large UK Caucasian cohort. <i>Arthritis and Rheumatism</i> , 2008, 58, 1275-1283.	6.7	40
530	Distinct topography of erosion and new bone formation in achilles tendon enthesitis: Implications for understanding the link between inflammation and bone formation in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2694-2699.	6.7	114
531	Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2993-2999.	6.7	187
532	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
533	Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1467-1474.	6.7	165
534	An ultrasonographic study of osteoarthritis of the hand: Synovitis and its relationship to structural pathology and symptoms. <i>Arthritis and Rheumatism</i> , 2008, 59, 1756-1763.	6.7	128
535	IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1516-1523.	0.5	951
536	TRPC channel activation by extracellular thioredoxin. <i>Nature</i> , 2008, 451, 69-72.	13.7	260
537	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. <i>Nature Genetics</i> , 2008, 40, 1156-1159.	9.4	143
538	Abatacept in the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008, 10, S5.	1.6	43
539	The development of targeted therapies in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2008, 31, 219-227.	3.0	37
540	Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. <i>Clinical Therapeutics</i> , 2008, 30, 70-83.	1.1	36

#	ARTICLE	IF	CITATIONS
541	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet, The</i> , 2008, 372, 375-382.	6.3	744
542	Role of oestrogen in the development of joint symptoms?. <i>Lancet Oncology, The</i> , 2008, 9, 817-818.	5.1	13
543	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. <i>Human Molecular Genetics</i> , 2008, 17, 2274-2279.	1.4	131
544	Predicting the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis. <i>Future Rheumatology</i> , 2008, 3, 441-444.	0.2	0
545	Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. <i>Journal of Rheumatology</i> , 2008, 35, 580-3.	1.0	11
546	Treating rheumatoid arthritis. <i>BMJ: British Medical Journal</i> , 2007, 335, 56-57.	2.4	8
547	The future of imaging in monitoring biologic therapy. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 2-3.	3.2	0
548	Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1513-1517.	0.5	41
549	Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 690-692.	0.5	10
550	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 778-781.	0.5	53
551	A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1669-1671.	0.5	8
552	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874.	6.3	859
553	Aspects of early arthritis. Biological therapy in early arthritis â€œ overtreatment or the way to go?. <i>Arthritis Research and Therapy</i> , 2007, 9, 211.	1.6	33
554	Recombinant human anti-â€œtransforming growth factor Î²1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
555	A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 154-160.	6.7	28
556	Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. <i>Arthritis and Rheumatism</i> , 2007, 57, 448-453.	6.7	73
557	The validity of the inclusion of â€œlupus headacheâ€œ in the systemic lupus erythematosus disease activity index. <i>Arthritis and Rheumatism</i> , 2007, 56, 2812-2813.	6.7	7
558	Development of psoriasis after B cell depletion with rituximab. <i>Arthritis and Rheumatism</i> , 2007, 56, 2715-2718.	6.7	231

#	ARTICLE	IF	CITATIONS
559	Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3496-3501.	6.7	49
560	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3896-3908.	6.7	310
561	Delay in imaging versus clinical response: A rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1564-1567.	6.7	67
562	Spondylarthrite ankylosante, positivité de HLA-B27 et utilisation des biothérapies. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 232-236.	0.0	1
563	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007, 39, 1431-1433.	9.4	361
564	The role of MRI and ultrasound as surrogate markers of structural efficacy of treatments in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2007, 74, 227-229.	0.8	6
565	Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. <i>Joint Bone Spine</i> , 2007, 74, 140-143.	0.8	39
566	Quantifying peri-meniscal synovitis and its relationship to meniscal pathology in osteoarthritis of the knee. <i>European Radiology</i> , 2007, 17, 119-124.	2.3	19
567	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. <i>Rheumatology International</i> , 2007, 27, 793-806.	1.5	85
568	Imaging Inflamed Synovial Joints. <i>Methods in Molecular Medicine</i> , 2007, 135, 3-26.	0.8	6
569	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007, 34, 501-9.	1.0	45
570	The OMERACT Magnetic Resonance Imaging Inflammatory Arthritis Group - advances and priorities. <i>Journal of Rheumatology</i> , 2007, 34, 852-3.	1.0	10
571	A multireader reliability study comparing conventional high-field magnetic resonance imaging with extremity low-field MRI in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 854-6.	1.0	25
572	A multicenter reliability study of extremity-magnetic resonance imaging in the longitudinal evaluation of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 857-8.	1.0	14
573	Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 859-61.	1.0	39
574	Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive disease. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 853-857.	1.3	0
575	Inhibiting toll-like receptors in inflammatory disease. <i>Lancet, The</i> , 2006, 368, 821-822.	6.3	5
576	Biomarkers: Strategies to predict outcome of rheumatoid arthritis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 11-16.	0.5	1

#	ARTICLE	IF	CITATIONS
577	Treatment of rheumatoid arthritis. <i>BMJ: British Medical Journal</i> , 2006, 332, 152-155.	2.4	111
578	Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. <i>Future Rheumatology</i> , 2006, 1, 293-302.	0.2	0
579	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 865.	2.0	643
580	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 702-710.	6.7	390
581	Ankylosing spondylitis: New treatment modalities. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 559-570.	1.4	11
582	Infliximab treatment maintains employability in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 716-722.	6.7	102
583	A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: Are they the same?. <i>Arthritis and Rheumatism</i> , 2006, 54, 1328-1333.	6.7	160
584	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 1390-1400.	6.7	951
585	Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1410-1414.	6.7	158
586	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis and Rheumatism</i> , 2006, 54, 2793-2806.	6.7	1,462
587	MR Imaging Findings in the Hands. <i>Radiology</i> , 2006, 241, 320-321.	3.6	2
588	Infliximab for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 193-207.	1.3	5
589	Nonresponse to tumor necrosis factor antagonists—is there any point in re-treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 288-289.	3.2	9
590	Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2559-2570.	0.9	34
591	Abatacept in the treatment of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 365-375.	0.9	36
592	Imaging in Ankylosing Spondylitis. , 2006, , 71-81.		2
593	Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. <i>Journal of Rheumatology</i> , 2006, 33, 681-9.	1.0	47
594	Introduction. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S37-S38.	0.5	0

#	ARTICLE	IF	CITATIONS
595	How should we manage early rheumatoid arthritis? From imaging to intervention. <i>Current Opinion in Rheumatology</i> , 2005, 17, 280-285.	2.0	24
596	Are early arthritis clinics necessary?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 1-17.	1.4	27
597	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept. <i>Arthritis and Rheumatism</i> , 2005, 52, 42-48.	6.7	102
598	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 27-35.	6.7	521
599	Study of individual joint pathology in rheumatoid arthritis suggests a single pathology: Comment on the editorial by Kirwan. <i>Arthritis and Rheumatism</i> , 2005, 52, 672-673.	6.7	0
600	Recommendations for musculoskeletal ultrasonography by rheumatologists: Setting global standards for best practice by expert consensus. <i>Arthritis and Rheumatism</i> , 2005, 53, 83-92.	6.7	94
601	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2263-2271.	6.7	456
602	Co-stimulatory blockade as therapy for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 400-406.	2.1	12
603	Potential for Altering Rheumatoid Arthritis Outcome. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 763-772.	0.8	17
604	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005, 7, R80.	2.0	75
605	Adalimumab therapy: Clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. <i>Drugs of Today</i> , 2005, 41, 155.	2.4	8
606	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 590-601.	1.0	68
607	Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1620-31.	1.0	26
608	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	1.0	132
609	Magnetic resonance imaging in rheumatoid arthritis advances and research priorities. <i>Journal of Rheumatology</i> , 2005, 32, 2462-4.	1.0	16
610	The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. <i>Journal of Rheumatology</i> , 2005, 32, 2465-9.	1.0	21
611	Imaging in early arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 927-943.	1.4	23
612	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor ? blockade. <i>Arthritis and Rheumatism</i> , 2004, 50, 725-728.	6.7	73

#	ARTICLE	IF	CITATIONS
613	The validity and predictive value of magnetic resonance imaging erosions in rheumatoid arthritis: Comment on the article by Goldbach-Mansky et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 1009-1011.	6.7	4
614	Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 817-827.	6.7	381
615	Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: Implications for pathogenesis and treatment. <i>Arthritis and Rheumatism</i> , 2004, 50, 2428-2432.	6.7	46
616	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3432-3443.	6.7	1,080
617	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. <i>Arthritis and Rheumatism</i> , 2004, 50, 4072-4073.	6.7	19
618	Practice, training, and assessment among experts performing musculoskeletal ultrasonography: Toward the development of an international consensus of educational standards for ultrasonography for rheumatologists. <i>Arthritis and Rheumatism</i> , 2004, 51, 1018-1022.	6.7	47
619	Review of health economics modelling in rheumatoid arthritis. <i>Pharmacoeconomics</i> , 2004, 22, 55-69.	1.7	22
620	Efficacy of B-Cell Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2004, 350, 2572-2581.	13.9	2,343
621	Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: imaging technique. <i>Current Opinion in Rheumatology</i> , 2004, 16, 435-442.	2.0	16
622	Phenotypical, Morphological and Molecular Analysis of Fresh Human Bone Marrow Mesenchymal/Stromal Stem Cells (MSCs) Enriched by Four Different Methods.. <i>Blood</i> , 2004, 104, 2337-2337.	0.6	3
623	Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. <i>Journal of Rheumatology</i> , 2004, 31, 482-8.	1.0	125
624	The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. <i>Journal of rheumatology Supplement, The</i> , 2004, 71, 13-20.	2.2	18
625	Leflunomide: a manageable safety profile. <i>Journal of rheumatology Supplement, The</i> , 2004, 71, 21-4.	2.2	43
626	Lefunomide in combination therapy. <i>Journal of rheumatology Supplement, The</i> , 2004, 71, 25-30.	2.2	2
627	Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography. <i>Best Practice and Research in Clinical Rheumatology</i> , 2003, 17, 513-528.	1.4	29
628	Pes planovalgus in RA: a descriptive and analytical study of foot function determined by gait analysis. <i>Musculoskeletal Care</i> , 2003, 1, 21-33.	0.6	46
629	Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 64-71.	6.7	440
630	Power doppler sonography: Improving disease activity assessment in inflammatory musculoskeletal disease. <i>Arthritis and Rheumatism</i> , 2003, 48, 285-288.	6.7	120

#	ARTICLE	IF	CITATIONS
631	Role of metacarpophalangeal joint anatomic factors in the distribution of synovitis and bone erosion in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1214-1222.	6.7	211
632	Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. <i>Arthritis and Rheumatism</i> , 2003, 48, 3039-3045.	6.7	98
633	Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. <i>Arthritis and Rheumatism</i> , 2003, 48, 3085-3095.	6.7	110
634	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	13.9	973
635	The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 673-681.	1.9	47
636	Angiopoietins, growth factors, and vascular morphology in early arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 260-8.	1.0	157
637	Gout related upper limb cellulitis: an ultrasound study. <i>Journal of Rheumatology</i> , 2003, 30, 417-9.	1.0	9
638	Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. <i>Journal of Rheumatology</i> , 2003, 30, 1102-7.	1.0	62
639	OMERACT Rheumatoid Arthritis MRI Studies Module. <i>Journal of Rheumatology</i> , 2003, 30, 1364-5.	1.0	13
640	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score. <i>Journal of Rheumatology</i> , 2003, 30, 1366-75.	1.0	91
641	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 4: an international multicenter longitudinal study using the RA-MRI Score. <i>Journal of Rheumatology</i> , 2003, 30, 1376-9.	1.0	67
642	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. <i>Journal of Rheumatology</i> , 2003, 30, 1385-6.	1.0	494
643	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. <i>Journal of Rheumatology</i> , 2003, 30, 1387-92.	1.0	72
644	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. <i>Journal of Rheumatology</i> , 2003, 30, 2287-91.	1.0	139
645	Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. <i>Drugs of Today</i> , 2003, 39 Suppl B, 17-23.	0.7	1
646	Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. <i>Journal of Rheumatology</i> , 2003, 30, 2572-9.	1.0	33
647	Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 290-297.	0.5	340
648	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002, 100, 4550-4556.	0.6	152

#	ARTICLE	IF	CITATIONS
649	Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes. <i>Arthritis Research</i> , 2002, 4, S6.	2.0	3
650	High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases. <i>International Immunopharmacology</i> , 2002, 2, 399-414.	1.7	7
651	Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. <i>Clinical Therapeutics</i> , 2002, 24, 1225-1291.	1.1	29
652	Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2002, 46, 366-372.	6.7	214
653	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 837-839.	6.7	44
654	The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. <i>Arthritis and Rheumatism</i> , 2002, 46, 489-493.	6.7	182
655	Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. <i>Arthritis and Rheumatism</i> , 2002, 46, 1971-1972.	6.7	23
656	Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002, 46, 1470-1479.	6.7	354
657	Magnetic resonance imaging as a predictor of progressive joint destruction in neuropathic joint disease. <i>Arthritis and Rheumatism</i> , 2002, 46, 2814-2815.	6.7	12
658	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. <i>Arthritis and Rheumatism</i> , 2002, 46, 2034-2038.	6.7	262
659	The geometric architecture of the subtalar and midtarsal joints in rheumatoid arthritis based on magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2002, 46, 3168-3177.	6.7	134
660	Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. <i>Arthritis and Rheumatism</i> , 2002, 46, 3349-3360.	6.7	563
661	Advances in the understanding of enthesal inflammation. <i>Current Rheumatology Reports</i> , 2002, 4, 500-506.	2.1	59
662	The concept of disease modification in spondyloarthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1583-5.	1.0	18
663	Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. <i>Journal of Rheumatology</i> , 2002, 29, 2371-8.	1.0	79
664	Evidence supporting the benefit of early intervention in rheumatoid arthritis. <i>Journal of Rheumatology Supplement</i> , The, 2002, 66, 3-8.	2.2	45
665	Infliximab: a new treatment for rheumatoid arthritis. <i>British Journal of Hospital Medicine</i> , 2001, 62, 150-152.	0.3	9
666	Combination therapy in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2001, 23, 165-183.	4.0	5

#	ARTICLE	IF	CITATIONS
667	Autologous stem cell transplantation for rapidly progressive jo-1-positive polymyositis with long-term follow-up. <i>British Journal of Haematology</i> , 2001, 113, 840-841.	1.2	25
668	Predictors of outcome in patients with oligoarthritis: Results of a protocol of intraarticular corticosteroids to all clinically active joints. <i>Arthritis and Rheumatism</i> , 2001, 44, 1177-1183.	6.7	46
669	Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2024-2028.	6.7	109
670	Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2001, 44, 2112-2117.	6.7	399
671	How do you diagnose rheumatoid arthritis early?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 49-66.	1.4	17
672	Imaging the joints in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 91-104.	1.4	31
673	Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific Association with Rheumatoid Arthritis. <i>Infection and Immunity</i> , 2001, 69, 1821-1831.	1.0	20
674	Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 125-137.	0.9	31
675	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. <i>Journal of Clinical Investigation</i> , 2001, 107, 519-528.	3.9	36
676	Leflunomide: a new DMARD for rheumatoid arthritis. <i>British Journal of Hospital Medicine</i> , 2000, 61, 344-347.	0.3	5
677	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. <i>Arthritis and Rheumatism</i> , 2000, 43, 1820-1830.	6.7	161
678	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. <i>Arthritis and Rheumatism</i> , 2000, 43, 2762-2770.	6.7	611
679	Synovial biopsy in arthritis research: five years of concerted European collaboration. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 506-511.	0.5	35
680	Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 504-505.	0.5	53
681	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	13.9	2,910
682	Autologous blood stem cell transplantation as therapy for autoimmune diseases. <i>Annals of Medicine</i> , 2000, 32, 615-621.	1.5	12
683	COX-1, COX-2: So What?: EDITORIAL REVIEW. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 6-9.	0.6	6
684	Established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 1999, 13, 561-575.	1.4	50

#	ARTICLE	IF	CITATIONS
685	Psoriatic arthritis: A unified concept twenty years on. <i>Arthritis and Rheumatism</i> , 1999, 42, 1080-1086.	6.7	269
686	The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: A controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 1999, 42, 1706-1711.	6.7	346
687	Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope. <i>Arthritis and Rheumatism</i> , 1999, 42, 2184-2188.	6.7	154
688	Spondyloarthropathy. <i>Lancet</i> , The, 1999, 353, 1526-1527.	6.3	3
689	An anatomical explanation for good-prognosis rheumatoid arthritis. <i>Lancet</i> , The, 1999, 353, 123-124.	6.3	157
690	Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. <i>Lancet</i> , The, 1999, 354, 2106-2111.	6.3	499
691	Infliximab (chimeric anti-tumour necrosis factor $\hat{\pm}$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	6.3	2,266
692	Enthesitis in spondyloarthropathy. <i>Current Opinion in Rheumatology</i> , 1999, 11, 244-250.	2.0	132
693	Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. <i>Arthritis and Rheumatism</i> , 1998, 41, 2196-2204.	6.7	920
694	Classification of inflammatory arthritis by enthesitis. <i>Lancet</i> , The, 1998, 352, 1137-1140.	6.3	553
695	Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis. <i>Pharmacoeconomics</i> , 1998, 14, 191-199.	1.7	19
696	Rheumatoid arthritis: not yet curable with early intensive therapy. <i>Lancet</i> , The, 1997, 350, 304-305.	6.3	21
697	1 What is early rheumatoid arthritis?: definition and diagnosis. <i>Bailliere's Clinical Rheumatology</i> , 1997, 11, 13-26.	1.0	35
698	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1838-1842.	6.7	25
699	The Clinical Implications of Inhibition of the Inducible Form of Cyclo-Oxygenase. <i>Drug Safety</i> , 1996, 15, 249-260.	1.4	30
700	Pirazolac. <i>BioDrugs</i> , 1996, 6, 511-511.	0.7	0
701	DXA scanning. <i>Bailliere's Clinical Rheumatology</i> , 1996, 10, 679-698.	1.0	4
702	New cyclo-oxygenase and cytokine inhibitors. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 731-758.	1.0	13

#	ARTICLE	IF	CITATIONS
703	Clinical Use of Cyclosporin in Rheumatoid Arthritis. <i>Drugs</i> , 1995, 50, 26-36.	4.9	23
704	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994, 24, 191-195.	1.6	212
705	Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. <i>Arthritis and Rheumatism</i> , 1994, 37, 1166-1170.	6.7	185
706	8-Hydroxydeoxyguanosine. <i>FEBS Letters</i> , 1994, 348, 131-138.	1.3	127
707	Cytokines and the Acute Phase Response in SLE. <i>Lupus</i> , 1993, 2, 345-347.	0.8	8
708	Carbocysteine polymorphism and disease. <i>Lancet, The</i> , 1992, 339, 616-617.	6.3	7
709	Techetium 99m methylene diphosphonate bone scanning in osteoarthritic hands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991, 18, 12-6.	2.2	28
710	Comment on article by Baer et al. <i>Arthritis and Rheumatism</i> , 1987, 30, 357-358.	6.7	3
711	061.â€fRituximab-Associated Neutropaenia: Safety of Retreatment Rituximab Therapy. <i>Rheumatology</i> , 0, , .	0.9	1
712	103â€fEfficacy of Rituximab in Patients with Rheumatoid Arthritis Associated with Bronchiectasis: Results from a Multicentre Cohort. <i>Rheumatology</i> , 0, , .	0.9	0
713	Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary SjÃ¶rgren Syndrome. <i>ACR Open Rheumatology</i> , 0, , .	0.9	2
714	Can biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission?. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0